BERWYN, Pa.– Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that on August 23, 2021 it entered into a license agreement with Pierre Fabre Farma de Mexico, S.A. de C.V. (Pierre Fabre), a subsidiary of the Pierre Fabre group which distribute products in over 100 countries around the world. Under the agreement, Amring granted to Pierre Fabre an exclusive royalty-bearing license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB) in Mexico.
“We are pleased to enter into the exclusive license agreement for LYSTEDA with Pierre Fabre that expands patient access to this medication,” stated Daniel Carbery, President and CEO of Amring. “We believe Pierre Fabre is a strong partner in the region.”
Stéphan Bergonzi, Pierre Fabre Farma de México’s CEO stated, “We are pleased to sign this licensing agreement between Pierre Fabre Farma de México and Amring Pharmaceuticals. This agreement guarantees the availability of LYSTEDA in Mexico for at least the next 5 years, allowing thousands of Mexican patients to keep continuing to benefit from it.”
